AI
Allostery Investments Portfolio holdings
AUM
$7.85M
This Quarter Return
+35.03%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$7.85M
AUM Growth
+$7.85M
(-89%)
Cap. Flow
-$64.5M
Cap. Flow
% of AUM
-821.28%
Top 10 Holdings %
Top 10 Hldgs %
82.66%
Holding
46
New
5
Increased
1
Reduced
14
Closed
26
Top Buys
| 1 |
Rezolute
RZLT
|
$532K |
| 2 |
Fulcrum Therapeutics
FULC
|
$278K |
| 3 |
Akero Therapeutics
AKRO
|
$240K |
| 4 |
Tango Therapeutics
TNGX
|
$205K |
| 5 |
Tourmaline Bio
TRML
|
$150K |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
$7.13M |
| 2 |
Merus
MRUS
|
$6.08M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$4.73M |
| 4 |
Apogee Therapeutics
APGE
|
$4.52M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$4.34M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$6.12B
| $1.28M | 16.31% | 167,350 -932,304 | -85% | -$7.13M |
|
|
2
Akero Therapeutics
AKRO
$3.74B
| $1.2M | 15.29% | 22,500 +4,500 | +25% | +$240K |
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $770K | 9.81% | 120,119 -145,980 | -55% | -$936K |
|
|
CNTA
4
Centessa Pharmaceuticals
CNTA
$2.25B
| $690K | 8.79% | 52,500 -330,024 | -86% | -$4.34M |
|
5
Evolus
EOLS
$494M
| $553K | 7.04% | 60,000 -352,754 | -85% | -$3.25M |
|
|
6
Rezolute
RZLT
$619M
| $532K | 6.78% | +119,294 | New | +$532K |
|
|
7
Merus
MRUS
$4.98B
| $473K | 6.03% | 9,000 -115,657 | -93% | -$6.08M |
|
|
8
KalVista Pharmaceuticals
KALV
$678M
| $452K | 5.76% | 40,000 -418,302 | -91% | -$4.73M |
|
|
9
Fulcrum Therapeutics
FULC
$351M
| $278K | 3.54% | +40,353 | New | +$278K |
|
|
10
Apogee Therapeutics
APGE
$2.17B
| $261K | 3.32% | 6,000 -104,000 | -95% | -$4.52M |
|
|
VRNA
11
Verona Pharma
VRNA
$9.16B
| $236K | 3.01% | 2,500 -10,000 | -80% | -$946K |
|
|
12
Tango Therapeutics
TNGX
$747M
| $205K | 2.61% | +40,000 | New | +$205K |
|
13
BridgeBio Pharma
BBIO
$9.89B
| $173K | 2.2% | 4,000 -76,000 | -95% | -$3.28M |
|
14
Cytokinetics
CYTK
$4.23B
| $165K | 2.1% | 5,000 -65,000 | -93% | -$2.15M |
|
|
15
Tourmaline Bio
TRML
$601M
| $150K | 1.91% | +9,356 | New | +$150K |
|
16
Legend Biotech
LEGN
$6.41B
| $142K | 1.81% | 4,000 -750 | -16% | -$26.6K |
|
17
Nektar Therapeutics
NKTR
$568M
| $103K | 1.32% | +4,000 | New | +$103K |
|
18
ProMIS Neurosciences
PMN
$28M
| $76.3K | 0.97% | 155,720 -77,983 | -33% | -$38.2K |
|
19
Arcellx
ACLX
$3.85B
| $65.9K | 0.84% | 1,000 -43,000 | -98% | -$2.83M |
|
20
Avalo Therapeutics
AVTX
$122M
| $44.9K | 0.57% | 9,000 -98,141 | -92% | -$490K |
|
21
Alkermes
ALKS
$4.78B
| – | – | -115,000 | Closed | -$3.8M |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| – | – | -7,500 | Closed | -$117K |
|
|
JBIO
23
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| – | – | -1,421,568 | Closed | -$3.57M |
|
24
Beam Therapeutics
BEAM
$1.66B
| – | – | -92,754 | Closed | -$1.81M |
|
25
Context Therapeutics
CNTX
$75.4M
| – | – | -950,166 | Closed | -$582K |
|